Accelerate Scalability & Smooth Regulatory Approval With Tightened QC of Oligos for Cost Efficient GMP Manufacturing  

With the unprecedented growth of the oligonucleotides market, reaching $2b by 2027 and with over 250 in the clinical phase of drug development, we now seek to unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets.

In the last 12 months alone, there have been a number of advances in the field with Switch Therapeutics advancing their first RNAi technology, Avidity turbocharging their antibody-oligo conjugate and Ansa Biotech successfully synthesising the world’s longest oligonucleotide! 

Despite this, drug developers still face challenges in manufacturability and lack of concrete regulatory protocols. The 2nd annual Oligonucleotides CMC & Analytical Development Summit is a dedicated forum to CMC and Analytical experts will unite 70+ industry leaders to leverage knowledge and share thought-leadership on: